Utah Cancer Specialists

Last Updated  May 1, 2020

Protoccol Number Indication Protocol NCT number
STA004 Advanced Solid Tumor A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of a Drug in Patients with Advanced Solid Tumors. NCT03416816
STA002 Advanced Solid Tumor A Phase 1 Study for Study Particiants with BRAFF V-600 Mutation In Melanoma  or Other Solid Tumors NCT03864042
BRE006 Breast A phase 3,  Randomized, Open-Label Trial to Evaluate Efficacy and Safety of a Drug with Endocrine Therapy as Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer NCT03701334
BRE007 Breast A phase II trial to compare efficacy of Study Drug in combination with Everolimus and Exemestane versus Everolimus and Exemestane in Post-Menopausal Women with HR+ / HER2- Metastatic Breast Cancer NCT03659136
BRE008 Breast  A Phase 3 Randomized, Open-Label, Active – Controlled, Multicenter Trial Emerald Study Drug VS. Standard of Care for theTreatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy NCT03778931
BRE009 Breast A Phase III Randomised Study Assessing the Efficacy andSafety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer NCT03997123
BRE010 Breast A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer NCT03961698
GAS001 Gastric A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating  a Drug  in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer NCT03694522
GAS002 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 L Treatment of Subjects with Claudin18.2+, HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction NCT03653507
LUN002 Lung NSCLC A Randomized, Double-Blind, Phase 3 Study of chemptherapy  With or Without a Drug in EGFR-Mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) NCT03515837
LUN003 Lung NSCLC A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of a Drug + Standard Therapy + a Study Drug with or without a drug as First-LineTreatment in Participants with Metastatic Nonsquamous NSCLC NCT03829319
LUN004 Lung SCLC  A Phase 3, Open-label,Randomized Study of a Drug Administered Sequentially with a Platinum Doublet or a Platinum Doublet Plus Study Drug in Third-
Line or Beyond Small Cell Lung Cancer
MDS001 MDS Low Risk A Phase3,Open-Label,Randomized Study to Compare the Efficiancy and Safety of Luspatercept versus Epoetin ALFA for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions NCT03682536
OVA005 Ovarian A Randomized, Double-Blind, Phase 3 Study Comaparison of Platinum-Based Therapy with Two Drugs Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III of IV Nonmucinous Epithelial Ovarian Cancer NCT03602859
PRO002 Prostate A Phase 1b-2 Study of a Drug in Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT03431350
PRO003 Prostate A Phase 3 Randomized, Placebo-controlled, Double-blind Study of a Drug in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Predisone for Treatment of Subjects with Metastatic Prostate Cancer NCT03748641
REN001 Renal A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Renal Cell Carcinoma NCT03961698
STA005 Advanced Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm)
and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
LEK001 Lekumia A Phase 2,Randomized Study of a Drug Versus Another Study Drug in Patients With CML-CP Who Have Been Previously Treated and Have Not Achieved Deep Molecular Response NCT03578367